Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price Target & Predictions
AMLX Stock Forecast
Amylyx Pharmaceuticals stock forecast is as follows: an average price target of $6.67 (represents a 27.53% upside from AMLX’s last price of $5.23) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AMLX Price Target
The average price target for Amylyx Pharmaceuticals (AMLX) is $6.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $3.00. This represents a potential 27.53% upside from AMLX's last price of $5.23.
AMLX Analyst Ratings
According to 5 Wall Street analysts, Amylyx Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AMLX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amylyx Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | Joel Beatty | Robert W. Baird | $11.00 | $4.76 | 131.09% | 110.33% |
| Oct 23, 2024 | Geoff Meacham | Bank of America Securities | $10.00 | $4.53 | 120.75% | 91.20% |
| Oct 18, 2024 | Andrew Fein | H.C. Wainwright | $8.00 | $3.92 | 104.08% | 52.96% |
| Oct 18, 2024 | Marc Goodman | Leerink Partners | $4.00 | $3.92 | 2.04% | -23.52% |
| May 14, 2024 | Graig Suvannavejh | Mizuho Securities | $3.00 | $1.82 | 64.84% | -42.64% |
| Apr 11, 2024 | Joel Beatty | Robert W. Baird | $3.00 | $2.46 | 21.95% | -42.64% |
| Apr 04, 2024 | Neena Bitritto-Garg | Deutsche Bank | $4.00 | $2.62 | 52.96% | -23.52% |
| Mar 17, 2024 | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.24 | 23.46% | -23.52% |
The latest Amylyx Pharmaceuticals stock forecast, released on Nov 18, 2024 by Joel Beatty from Robert W. Baird, set a price target of $11.00, which represents a 131.09% increase from the stock price at the time of the forecast ($4.76), and a 110.33% increase from AMLX last price ($5.23).
Amylyx Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 4 | 8 |
| Avg Price Target | $10.50 | $8.25 | $5.88 |
| Last Closing Price | $5.23 | $5.23 | $5.23 |
| Upside/Downside | 100.76% | 57.74% | 12.43% |
In the current month, the average price target of Amylyx Pharmaceuticals stock is $10.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 100.76% increase as opposed to Amylyx Pharmaceuticals's last price of $5.23. This month's average price target is up 27.27% compared to last quarter, and up 78.57% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | Bank of America Securities | - | Buy | Upgrade |
| Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 18, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Jul 12, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Jul 11, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jun 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 08, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Apr 04, 2024 | Deutsche Bank | Buy | Buy | Hold |
Amylyx Pharmaceuticals's last stock rating was published by Bank of America Securities on Oct 23, 2024. The company Upgrade its AMLX rating from "null" to "Buy".
Amylyx Pharmaceuticals Financial Forecast
Amylyx Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $102.69M | - | $71.43M | $21.89M | $345.00K | - | - | - |
| Avg Forecast | $44.60M | $47.55M | $52.43M | $58.15M | $32.59M | $31.57M | $10.66M | $98.35M | $106.96M | $113.66M | $92.21M | $58.99M | $4.72M | $83.33K | $125.00K | $83.33K | $338.33K |
| High Forecast | $44.60M | $47.55M | $52.43M | $58.15M | $32.59M | $31.57M | $11.55M | $98.35M | $109.27M | $117.63M | $92.21M | $58.99M | $4.72M | $83.33K | $125.00K | $83.33K | $338.33K |
| Low Forecast | $44.60M | $47.55M | $52.43M | $58.15M | $32.59M | $31.57M | $9.77M | $98.35M | $104.76M | $110.32M | $92.21M | $58.99M | $4.72M | $83.33K | $125.00K | $83.33K | $338.33K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | - | 1.21% | 4.63% | 4.14% | - | - | - |
Amylyx Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $106.96M, with a low forecast of $104.76M, and a high forecast of $109.27M. AMLX's average Quarter revenue forecast represents a 4.15% increase compared to the company's last Quarter revenue of $102.69M (Sep 23).
Amylyx Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $18.72M | - | $-2.05M | $-44.59M | $-54.52M | $-54.15M | $-47.78M | $-87.91M |
| Avg Forecast | $-18.86M | $-20.11M | $-22.17M | $-24.58M | $-13.78M | $-13.35M | $-4.51M | $-41.58M | $-45.22M | $-48.06M | $-38.99M | $-24.94M | $-2.00M | $-64.92K | $-97.38K | $-36.31M | $-263.58K |
| High Forecast | $-18.86M | $-20.11M | $-22.17M | $-24.58M | $-13.78M | $-13.35M | $-4.13M | $-41.58M | $-44.29M | $-46.64M | $-38.99M | $-24.94M | $-2.00M | $-64.92K | $-97.38K | $-29.05M | $-263.58K |
| Low Forecast | $-18.86M | $-20.11M | $-22.17M | $-24.58M | $-13.78M | $-13.35M | $-4.88M | $-41.58M | $-46.20M | $-49.73M | $-38.99M | $-24.94M | $-2.00M | $-64.92K | $-97.38K | $-43.57M | $-263.58K |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.39% | - | 0.08% | 22.33% | 839.74% | 556.04% | 1.32% | 333.52% |
3 analysts predict AMLX's average Quarter EBITDA for Dec 23 to be $-45.22M, with a high of $-44.29M and a low of $-46.20M. This is -341.58% lower than Amylyx Pharmaceuticals's previous annual EBITDA (Sep 23) of $18.72M.
Amylyx Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $20.89M | - | $1.57M | $-42.70M | $-53.76M | $-54.07M | $-47.85M | $-87.90M |
| Avg Forecast | $-42.22M | $-44.94M | $-44.94M | $-43.24M | $-38.40M | $-47.94M | $-49.71M | $-272.37K | $15.51M | $29.79M | $12.94M | $-16.38M | $-55.81M | $-66.09M | $-59.35M | $-36.36M | $-471.75M |
| High Forecast | $-42.22M | $-44.94M | $-44.94M | $-43.24M | $-36.05M | $-47.94M | $-49.71M | $-272.37K | $20.17M | $31.82M | $12.94M | $-16.38M | $-55.81M | $-66.09M | $-59.35M | $-29.09M | $-471.75M |
| Low Forecast | $-42.22M | $-44.94M | $-44.94M | $-43.24M | $-39.97M | $-47.94M | $-49.71M | $-272.37K | $9.31M | $25.05M | $12.94M | $-16.38M | $-55.81M | $-66.09M | $-59.35M | $-43.64M | $-471.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.70% | - | -0.10% | 0.77% | 0.81% | 0.91% | 1.32% | 0.19% |
Amylyx Pharmaceuticals's average Quarter net income forecast for Dec 23 is $15.51M, with a range of $9.31M to $20.17M. AMLX's average Quarter net income forecast represents a -25.75% decrease compared to the company's last Quarter net income of $20.89M (Sep 23).
Amylyx Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $48.72M | - | $44.01M | $40.84M | $29.94M | $29.99M | $26.35M | $38.93M |
| Avg Forecast | $1.50B | $1.60B | $1.76B | $1.96B | $1.10B | $1.06B | $358.59M | $3.31B | $3.60B | $3.82B | $3.10B | $1.98B | $158.87M | $2.80M | $4.20M | $2.80M | $11.38M |
| High Forecast | $1.50B | $1.60B | $1.76B | $1.96B | $1.10B | $1.06B | $388.49M | $3.31B | $3.67B | $3.96B | $3.10B | $1.98B | $158.87M | $2.80M | $4.20M | $2.80M | $11.38M |
| Low Forecast | $1.50B | $1.60B | $1.76B | $1.96B | $1.10B | $1.06B | $328.50M | $3.31B | $3.52B | $3.71B | $3.10B | $1.98B | $158.87M | $2.80M | $4.20M | $2.80M | $11.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.01% | - | 0.02% | 0.26% | 10.68% | 7.13% | 9.40% | 3.42% |
Amylyx Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $3.60B, based on 3 Wall Street analysts, with a range of $3.52B to $3.67B. The forecast indicates a 7283.50% rise compared to AMLX last annual SG&A of $48.72M (Sep 23).
Amylyx Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $0.31 | - | $0.02 | $-0.65 | $-0.92 | $-0.93 | $-0.93 | $-1.56 |
| Avg Forecast | $-0.62 | $-0.66 | $-0.66 | $-0.64 | $-0.56 | $-0.70 | $-0.73 | $-0.00 | $0.23 | $0.44 | $0.19 | $-0.24 | $-0.82 | $-0.97 | $-0.87 | $-0.69 | $-6.93 |
| High Forecast | $-0.62 | $-0.66 | $-0.66 | $-0.64 | $-0.53 | $-0.70 | $-0.73 | $-0.00 | $0.30 | $0.47 | $0.19 | $-0.24 | $-0.82 | $-0.97 | $-0.87 | $-0.69 | $-6.93 |
| Low Forecast | $-0.62 | $-0.66 | $-0.66 | $-0.64 | $-0.59 | $-0.70 | $-0.73 | $-0.00 | $0.14 | $0.37 | $0.19 | $-0.24 | $-0.82 | $-0.97 | $-0.87 | $-0.69 | $-6.93 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.71% | - | -0.08% | 0.79% | 0.95% | 1.07% | 1.35% | 0.22% |
According to 3 Wall Street analysts, Amylyx Pharmaceuticals's projected average Quarter EPS for Dec 23 is $0.23, with a low estimate of $0.14 and a high estimate of $0.30. This represents a -26.51% decrease compared to AMLX previous annual EPS of $0.31 (Sep 23).
Amylyx Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
| INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
| PDSB | PDS Bio | $2.03 | $9.00 | 343.35% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.37 | $7.00 | 195.36% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
| MREO | Mereo BioPharma Group | $3.58 | $6.75 | 88.55% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.23 | $6.67 | 27.53% | Buy |
| HOOK | HOOKIPA Pharma | $2.72 | $3.00 | 10.29% | Buy |